PROTEIN ANTIGEN-BINDING MOLECULES

The present disclosure provides antigen-binding molecule capable of binding to a sarbecovirus spike protein from two or more different sarbecovirus. Nucleic acids, expression 5 vectors, and cells for making and using the same. In particular antigen-binding molecules such as neutralising antibodies capable of inhibiting interaction between the sarbecovirus spike protein and ACE2, thus behaving as antagonists of infection of ACE2-expressing cells by the sarbecovirus. Antigen-binding molecules described herein are provided with a combination of advantageous properties over known SARS-CoV-2 antibodies..

Medienart:

Patent

Erscheinungsjahr:

2023

Erschienen:

2023

Enthalten in:

Europäisches Patentamt - (2023) vom: 14. Dez. Zur Gesamtaufnahme - year:2023

Sprache:

Englisch

Beteiligte Personen:

WANG LINFA [VerfasserIn]
CHIA WAN NI [VerfasserIn]
TAN CHEE WAH [VerfasserIn]
ZHU FENG [VerfasserIn]

Links:

Volltext [kostenfrei]

Themen:

Sonstige Themen:
615
A61K: Preparations for medical, dental, or toilet purpose (...)
A61P: Specific therapeutic activity of chemical compounds (...)
C07K: Peptides (peptides containing β-lactam rings c07d; (...)
che

Anmerkungen:

Source: www.epo.org (no modifications made), First posted: 2023-12-14, Last update posted on www.tib.eu: 2024-02-26, Last updated: 2024-03-01

Patentnummer:

AU2022278949

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

EPA018868118